How CancerScan’s Technology Could Be Used in the Future
CancerScan is an ambitious European research initiative developing a new generation of smart pathology technology. At its core is a system designed to transform standard biopsy slides into patient-specific “tumour digital twins”—virtual models that simulate how a tumour might respond to different treatments. While still in an early research phase, the project is already exploring how these innovations could eventually be translated into practical applications and reach real-world users.
Because CancerScan is developing a diverse set of innovations—including software, biological methods, and hardware—its exploitation strategy follows several distinct pathways. Each route is tailored to the specific type of result, helping ensure that future applications can be developed and brought to market in the most appropriate way.
Clinical Deployment Route: For Integrated, High‑Impact Medical Systems
Results such as the integrated platform that combines digital pathology, simulation, and clinical validation—are intended for future use in hospitals. These results require:
- regulatory approval,
- quality management systems,
- clinical validation, and
- a commercial entity capable of supporting medical deployment.
Who this route serves: Patients, oncologists, pathology departments, and cancer centres.
Why it matters: It enables personalised treatment planning by predicting how a tumour might respond to therapy.
Research & Academic Licensing Route: For Tools That Advance Scientific Understanding
Results such as the tumour simulation framework or advanced data‑integration methods, can be used directly by researchers without needing clinical certification.
These can be shared through academic licenses, open or semi‑open research collaborations, software tools for computational oncology or systems biology.
Who this route serves: Universities, research institutes, and scientific groups studying cancer biology.
Why it matters: It accelerates discovery, supports reproducible science, and builds a community around the technology.
Industry Collaboration Route: For Technologies Useful in Drug Development
Organoid‑based validation methods or mechanistic modelling are highly relevant for pharmaceutical R&D.
These can be exploited through project‑based partnerships, co‑development agreements, or licensing for preclinical testing workflows.
Who this route serves: Pharmaceutical and biotech companies developing new cancer therapies.
Why it matters: It helps companies understand how drugs behave in complex tumour environments and supports more informed decision‑making in early development.
Component‑Level Commercialisation Route: For Technologies With Broader Applications
CancerScan includes several specialised technologies, such as hardware acceleration, machine‑learning models, or knowledge‑graph methods, that can be used independently of the main system.
These components can follow their own exploitation paths, such as: licensing to technology companies, integration into other medical or scientific devices, use in broader digital health or AI applications.
Who this route serves: Medical device manufacturers, AI developers, digital health companies.
Why it matters: It ensures that valuable innovations do not remain locked inside a single product but can benefit wider fields.
CancerScan’s exploitation approach intentionally blends near‑term routes, such as research licensing or pharma partnerships, and long‑term routes such clinical deployment. This dual strategy ensures that early results can already support research and innovation, the full clinical vision can be pursued responsibly and sustainably, and each partner can exploit their own contributions appropriately.
CancerScan’s exploitation pathways reflect the diversity of its innovations. Instead of a single commercialisation plan, the project embraces multiple routes so that:
- patients may one day benefit from more personalized cancer treatment,
- clinicians gain tools that support complex decision‑making,
- researchers access advanced models and datasets,
- industry partners can use validated methods to improve drug development.
By tailoring the exploitation route to the type of result, CancerScan maximises the chances that its innovations will create real, lasting impact.
Links
Project website: https://www.cancerscanproject.eu/
LinkedIn channel: http://www.linkedin.com/company/cancerscan-project
X channel: https://x.com/CancerScan_eu
YouTube channel: https://www.youtube.com/@cancerscan-Project
Keywords
digital pathology, tumour digital twins, precision oncology, technology exploitation, research commercialisation, clinical decision support, pharma collaboration, academic licensing, innovation pathways, medical technology translation, oncology research tools, healthcare innovation, biomedical AI, clinical adoption
